Product
Xevinapant
Aliases
Debio 1143, Xevinapant (Debio 1143)
8 clinical trials
7 indications
Indication
Head and Neck CancerIndication
HealthyIndication
Head and Neck NeoplasmsIndication
Squamous Cell Carcinoma of Head and NeckIndication
Head and Neck Squamous Cell CarcinomaIndication
High-grade gliomaClinical trial
A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)Status: Recruiting, Estimated PCD: 2027-10-05
Clinical trial
A Single Arm, Open Label, Phase 1b Study of Xevinapant in Combination With Weekly Cisplatin and Intensity-modulated Radiotherapy to Assess Safety and Tolerability in Participants With LA SCCHN, Suitable for Definitive Chemoradiotherapy (HyperlynX)Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Single-dose, Open-label, Single Arm Study to Investigate PK of Xevinapant (Debio 1143) and Its Metabolite, D-1143-MET1 in Healthy East Asian ParticipantsStatus: Completed, Estimated PCD: 2023-04-21
Clinical trial
A Phase I Study of Xevinapant With Radiation and Concurrent Carboplatin and Paclitaxel in Patients Ineligible for Cisplatin With Locoregionally Advanced Squamous Cell Carcinoma of the Head and NeckStatus: Active (not recruiting), Estimated PCD: 2027-10-01
Clinical trial
Radiotherapy Plus Xevinapant or Placebo in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: a Randomized Phase II Study RAVINAStatus: Recruiting, Estimated PCD: 2029-07-01
Clinical trial
A Double-blind, Randomized, Phase III Study of Radiotherapy Combined With cetuXimab + Xevinapant Compared to Radiotherapy Combined With Cetuximab (Standard of Care) + Placebo in Patients With LA SCCHN, Unfit for High-dose CisplatinStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 1, Open-Label Window-of-Opportunity Study to Assess the Pharmacokinetics, Pharmacodynamics and Central Nervous System (CNS) Penetration of Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)Status: Not yet recruiting, Estimated PCD: 2027-06-01